BridgeBio Oncology (HLXB) CFO Caleb Tripp files voluntary Form 4 exit

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. insider update: Former Chief Financial Officer Caleb Tripp filed a voluntary Form 4 “exit” report stating he is no longer the company’s CFO as of August 11, 2025.

The filing notes that he had no transactions in the company’s securities that required disclosure in this report and that no securities are beneficially owned by him. The form is administrative in nature and confirms that he is no longer subject to Section 16 insider reporting requirements.

Insights

Corporate governance analyst

Filing confirms CFO role ended and no shares or trades to report.

The report shows that Caleb Tripp, formerly Chief Financial Officer of BridgeBio Oncology Therapeutics, Inc., is no longer in that role as of August 11, 2025. It is explicitly described as a voluntary “exit” report, which is commonly used to document that an insider is no longer subject to Section 16 reporting.

The filing states that there were no transactions in the issuer’s securities to disclose and that no securities are beneficially owned by the reporting person. The document is therefore administrative, confirming a change in reporting status rather than revealing new trading activity or ownership stakes. Any broader implications of the CFO transition would typically appear in other company disclosures.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tripp Caleb

(Last) (First) (Middle)

C/O HELIX ACQUISITION CORP. II

200 CLARENDON STREET, 52ND FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This is a voluntary "exit" report, filed solely to report that the Reporting Person is no longer the Issuer's Chief Financial Officer, effective as of August 11, 2025, and therefore is no longer subject to Section 16 reporting. The Reporting Person did not have any transactions in the Issuer's securities requiring disclosure in this voluntary "exit" report. No securities are beneficially owned.

	/s/ Caleb Tripp	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 4 for HLXB disclose about Caleb Tripp?

The Form 4 shows that Caleb Tripp filed a voluntary “exit” report indicating he is no longer Chief Financial Officer of BridgeBio Oncology Therapeutics, Inc. as of August 11, 2025.

Were any HLXB shares bought or sold in this Form 4 filing?

No. The filing explicitly states that the reporting person did not have any transactions in the issuer’s securities requiring disclosure in this voluntary exit report.

Does Caleb Tripp still own BridgeBio Oncology Therapeutics (HLXB) securities?

According to the filing, no securities are beneficially owned by Caleb Tripp as of this report.

Why did BridgeBio Oncology’s former CFO file a voluntary exit Form 4?

The report is filed solely to state that the reporting person is no longer the issuer’s Chief Financial Officer as of August 11, 2025 and therefore is no longer subject to Section 16 reporting.

Is this HLXB Form 4 part of a Rule 10b5-1 trading plan?

The document includes the standard checkbox for Rule 10b5-1(c) plans, but the remarks clarify there were no transactions to report in this exit filing.

Does the exit Form 4 for HLXB indicate any indirect or entity-held ownership by Caleb Tripp?

No. The filing states that no securities are beneficially owned, and there are no reported transactions or indirect holdings listed.